Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
In subsequent Phase 2 trials, once-weekly subcutaneous injections of retatrutide at doses of 4 mg, 8 mg, and 12 mg resulted in marked improvements in glycemic control compared to placebo, along with substantial weight loss when contrasted with placebo and dulaglutide (1.5 mg)
The Effect of Abdominal Exercise on Abdominal Fat
GLP-1 RAs and dual-action agonists like tirzepatide have been shown to control blood sugar effectively, making them a viable option for many diabetes patients
The dose-response relationship was clear across the REDEFINE 2 trial's range of 0.3 mg to 4.5 mg weekly, with higher doses consistently producing greater weight reductions
Statements Author contributions AA: Project administration, Formal analysis, Resources, Data curation, Writing original draft, Methodology, Visualization, Conceptualization, Supervision, Investigation, Validation, Software, Funding acquisition, Writing review & editing
US$ 25.33
US$ 27.81
US$ 21.60
